Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

120P - Neoadjuvant immunochemotherapy of pembrolizumab plus chemotherapy in resectable non-small cell lung cancer


31 Mar 2023


Poster Display session


Yulong Chen


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


Y. Chen1, B. Yan2, J. You2

Author affiliations

  • 1 Tianjin/CN
  • 2 Tianjin Medical University Cancer Institute & Hospital, Tianjin/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 120P


Neoadjuvant immunotherapy, as the focus of current research and treatment means for long-term survival, has become one of the options in supporting primary treatment intervention in early NSCLC.


This was a retrospective analysis of patients with locally resectable NSCLC, who received the neoadjuvant drug pembrolizumab plus chemotherapy and underwent surgical resection. The pathology responses and the PFS and OS in the total sample and subgroups were determined and analyzed. Additionally, artificial intelligence was utilized to incorporate multiple factors for developing a high-performance prediction model.


Of the 61 patients included in the retrospective analysis, 31 (50.82%) patients achieved a pCR, and 38 (62.30%) patients obtained an MPR. For the OS, patients with a pCR were significantly better than the patients with non-pCR (HR, 0.093; P = 0.0227); patients with an MPR performed significantly better than the patients with non-MPR (HR, 0.05357; P = 0.0169). Patients with lymph node metastasis after surgery had significantly worse OS and PFS than those without lymph node metastasis (HR, 0.01607; p = 0.0004; HR, 0.08757; p = 0.0004). The PFS of patients with SCC was better than the patients with non-SCC (HR, 0.3939; p = 0.0340). No significant differences in OS and PFS were found between 2 cycles vs. 3 cycles of neoadjuvant therapy before the surgery; ≤5 cycles vs. >5 cycles of adjuvant therapy post-surgery; TPS of <50% vs. ≥50% (P > 0.05). After model training and optimization, and 5-fold cross-validation, KNC (K-Neighbors Classifier) algorithm was able to predict the pCR with an 85.71% accuracy.


Neoadjuvant immunochemotherapy of pembrolizumab plus chemotherapy for non-small cell lung cancer is safe and tolerable. Both pCR and MPR were closely related to OS and PFS, reflecting the good response of tumor tissues to drug therapy. Lymph node metastasis after surgery was a poor prognostic factor, causing worse OS and PFS. Artificial intelligence constructed a prediction model for assessing treatment efficacy.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.